NeoStem, Inc. To Host Key Opinion Leader Event Webcast On December 1, 2014
NEW YORK, Nov. 26, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 to 5:30 PM EST.
The webcast will feature a presentation by Timothy Henry, MD, Director of Cardiology at the Cedars-Sinai Heart Institute, who will discuss the significance of the Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial, the results of which were previously announced on November 17th. (http://www.neostem.com/media/press-releases/news-item/initial-preserve-data/) Dr. Henry is an internationally recognized expert in the treatment of patients with refractory angina and acute myocardial infarction, with a focus on stem cell therapies. Before joining Cedars-Sinai, Dr. Henry was the Director of Research at the Minneapolis Heart Institute Foundation, at Abbott Northwestern Hospital in Minneapolis and at Hennepin County Medical Center, Minneapolis, as Director of Interventional Cardiology and Director of Cardiac Catheterization Laboratory. Dr. Henry has co-authored nearly 250 manuscripts and book chapters in prominent peer reviewed journals including Circulation Research, Journal of the American Medical Association, Lancet and European Heart Journal. Dr. Henry has served as editor and reviewer for several publications and is a board member of the American Heart Journal, Catheterization and Cardiovascular Interventions and Cardiovascular Business. He is widely sought after as guest lecturer on both the national and international level.
Key members of NeoStem's executive management team, including Chairman and CEO, Robin Smith, MD, MBA, and Chief Medical Officer, Douglas Losordo, MD, will also be in attendance to answer questions regarding the Company and the released data.
The live webcast of the event will be available at http://www.neostem.com/investors/investor-events. The event can also be accessed by calling 1-855-235-8282 and providing Conference ID 40994522.
About NeoStem's Ischemic Repair Program
NeoStem is developing therapies to address ischemia through its Ischemic Repair Program (the Program), using CD34 cell technology. Ischemia occurs when the supply of oxygenated blood in the body is restricted. The Company's therapeutics seek to reverse this restriction through the development and formation of new blood vessels. The Program's lead product candidate is NBS10, a chemotactic hematopoietic stem cell product comprised of autologous bone marrow derived CD34/CXCR4 cells selected to treat damaged heart muscle following AMI (or heart attack). NBS10 is thought to work by increasing microvascular blood flow in the heart muscle via the development and formation of new blood vessels, thereby reversing the restriction of blood supply caused by a heart attack and rescuing at-risk cardiac tissue from eventual cell death.
About the PreSERVE AMI Clinical Trial
PreSERVE AMI is a randomized, double-blind, placebo-controlled clinical trial of intracoronary infusion of autologous CD34 cells in patients with left ventricular dysfunction post-ST elevation myocardial infarction (STEMI). The trial included 161 subjects at 60 sites in the United States, randomized 1:1 between treatment and placebo arms. Eligible patients presented with acute STEMI, had successful stenting of the infarct-related artery and had left ventricular dysfunction 4 days after AMI. Primary endpoints include occurrence of SAEs and MACE (defined as cardiovascular death, re-infarction, heart failure hospitalization, and coronary revascularization) through 3 year follow-up, occurrence of SAEs through 3 year follow-up, and 6-month change in myocardial perfusion (RTSS) measured quantitatively by gated SPECT myocardial perfusion imaging. Other endpoints include cardiovascular magnetic imaging resonance (CMR) to measure left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-systolic diameter (LVEDV), regional myocardial strain, infarct/peri-infarct regional wall motion abnormalities and infarct size (baseline and six months) and quality of life measures (KCCQ and SAQ). While all 6 month data has been collected, it is subject to ongoing analysis, and results reported at this time, although promising, are preliminary. There can be no assurance that further analysis may not reveal negative, or less promising, results.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, Ischemic Repair Program (including NBS10 for AMI), Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
CONTACT: Investor Contact: LifeSci Advisors, LLC Hans Vitzthum Managing Director Phone: +1-212-915-2568 Email: hans@lifesciadvisors.com Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@neostem.com 